Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: DR Michael Austin

Back to Search
Wrench B, Szlosarek P, Fernandez M, Gribben J, bomalaski J, Kalampalika F, Kesmez R, Patel S et al. ( 2025 ) . Exploiting arginine auxotrophy in Philadelphia-chromosome positive acute lymphoblastic leukemia to deliver personalised metabolomic treatment . Conference: American Society of Haematology
Austin M, Patel S, Kesmez R, Kalampalika F, Bomalaski J, Gribben J, Fernandez MG, Szlosarek P et al. ( 2025 ) . Exploiting arginine auxotrophy in Philadelphia-chromosome positive acute lymphoblastic leukemia to deliver personalised metabolomic treatment . Blood vol. 146 , ( Supplement 1 )
Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James SC, Atkinson S, Durko J et al. ( 2024 ) . Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation . Leukemia vol. 38 , ( 11 ) 2395 - 2409 .
Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H et al. ( 2024 ) . Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS . Blood Neoplasia vol. 1 , ( 3 )
Di Mambro A, Arroyo-Berdugo Y, Fioretti T, Randles M, Cozzuto L, Rajeeve V, Cevenini A, Austin MJ et al. ( 2023 ) . SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML . Oncogene vol. 42 , ( 50 ) 3670 - 3683 .
Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin MJ, Latif A-L et al. ( 2023 ) . Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy . Blood vol. 143 , ( 4 ) 336 - 341 .
Austin MJ, Kalampalika F, Cawthorn WP, Patel B ( 2023 ) . Turning the spotlight on bone marrow adipocytes in haematological malignancy and non‐malignant conditions . British Journal of Haematology vol. 201 , ( 4 ) 605 - 619 .
Dembitz V, Lawson H, Philippe C, Burt RJ, James S, Magee ASM, Woodley K, Durko J et al. ( 2022 ) . Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia . Blood vol. 140 , ( Supplement 1 ) 3058 - 3060 .
Othman J, Tiong IS, Mokretar K, Ivey A, Austin MJ, Latif A-L, Crawley C, Amer M et al. ( 2022 ) . Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy . Blood vol. 140 , ( Supplement 1 ) 2033 - 2035 .
Patel BR, Castleton AZ, Austin MJ ( 2022 ) . Fast Facts for Patients: Waldenström Macroglobulinemia . Karger Publishers
Wrench B, Castleton A, Austin M ( 2022 ) . Fast Facts: Acute Lymphoblastic Leukemia . Karger Publishers
Othman J, Afzal U, Amofa R, Austin MJ, Bashford A, Belsham E, Byrne J, Coats T et al. ( 2021 ) . Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service . Blood vol. 138 , ( Supplement 1 )
Othman J, Amer M, Amofa R, Anderson L, Austin MJ, Bashford A, Belsham E, Boot J et al. ( 2021 ) . Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service . Blood vol. 138 , ( Supplement 1 )
Austin MJ, Halim L, Miraki-Moud F, Taussig D, Bomalaski J, Maher J, Gribben J, Szlosarek P et al. ( 2021 ) . Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T . Blood vol. 138 , ( Supplement 1 )
Heydt Q, Xintaropoulou C, Clear A, Austin M, Pislariu I, Miraki-Moud F, Cutillas P, Korfi K et al. ( 2021 ) . Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence . Nature Communications vol. 12 , ( 1 )
Mambro AD, Arroyo Y, Fioretti T, Randles M, Cozzuto L, Rajeeve V, Cevenini A, Austin MJ et al. . SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML .
Back to Search